BAFF-based trifunctional T-cell engagers trigger robust tumor immunity against B-cell malignancies

Abstract

Advancements in protein engineering have driven the continuous optimization of T-cell engagers (TCEs), resulting in remarkable clinical outcomes in the treatment of B-cell malignancies. Moreover, developing tri- or multispecific TCEs has emerged as a promising strategy to address the challenges of tumor heterogeneity and antigen escape. However, considerable obstacles remain, primarily in format design. In this study, we engineered BAFF-based TCEs with various formats that incorporate anti-CD3 Fab or IgG domains fused with BAFF ligands to target BAFF receptors (BAFFR, BCMA, and TACI). These constructs varied in valency and the presence or absence of long-acting elements such as Fc domains or the albumin binding domain consensus sequence (ABDCon). Although the inclusion of an Fc domain did not enhance sustained tumor eradication, variations in valency and spatial configuration profoundly influenced cytotoxicity. We identified TriBAFF/CD3/ABDCon as the optimal trifunctional construct, featuring an anti-CD3 Fab backbone with BAFF and ABDCon fused to the C-termini of the heavy and light chains. This design facilitates optimal immune synapse formation between the target cells and T cells and effectively controls tumor burdens in various B-cell malignancy models with good tolerability. Notably, TriBAFF/CD3/ABDCon outperformed conventional therapies, including blinatumomab and BAFF-based CAR-T cells, in models of heterogeneous leukemia and aggressive lymphoma. These findings underscore the potential of using natural ligands as antibody-targeting modules and provide valuable insights into the design of the next generation of multispecific TCEs, which hold promise for improving treatment outcomes in a wide range of malignancies and beyond.

Keywords

T-cell engager / natural ligand / multispecific antibody / B-cell malignancy / antibody engineering / immune escape

References

[1] Al Hadidi S , Heslop HE , Brenner MK et al. Bispecific antibodies and autologous chimeric antigen receptor T cell therapies for treatment of hematological malignancies. Mol Ther 2024; 32: 2444- 2460.

[2] Amini L , Silbert SK , Maude SL et al. Preparing for CAR T cell therapy: patient selection, bridging therapies and lymphodepletion. Nat Rev Clin Oncol 2022; 19: 342- 355.

[3] Arvedson T , Bailis JM , Urbig T et al. Considerations for design, manufacture, and delivery for effective and safe T-cell engager therapies. Curr Opin Biotechnol 2022; 78: 102799.

[4] Bacac M , Colombetti S , Herter S et al. CD20-TCB with obinutuzumab pretreatment as next-generation treatment of hematologic malignancies. Clin Cancer Res 2018; 24: 4785- 4797.

[5] Bargou R , Leo E , Zugmaier G et al. Tumor regression in cancer patients by very low doses of a T cell-engaging antibody. Science 2008; 321: 974- 977.

[6] Brinkmann U , Kontermann RE . The making of bispecific antibodies. MAbs 2017; 9: 182- 212.

[7] Calzada-Fraile D , Iborra S , Ramírez-Huesca M et al. Immune synapse formation promotes lipid peroxidation and MHC-I upregulation in licensed dendritic cells for efficient priming of CD8⁺ T cells. Nat Commun 2023; 14: 6772.

[8] Cao YJ , Wang X , Wang Z et al. Switchable CAR-T cells outperformed traditional antibody-redirected therapeutics targeting breast cancers. ACS Synth Biol 2021a; 10: 1176- 1183.

[9] Cao YJ , Yu C , Wu K-L et al. Synthesis of precision antibody conjugates using proximity-induced chemistry. Theranostics 2021b; 11: 9107- 9117.

[10] Cappell KM , Kochenderfer JN . Long-term outcomes following CAR T cell therapy: what we know so far. Nat Rev Clin Oncol 2023; 20: 359- 371.

[11] Chakraborty AK , Weiss A . Insights into the initiation of TCR signaling. Nat Immunol 2014; 15: 798- 807.

[12] Chen L , Qian W , Pan F et al. A trispecific antibody induces potent tumor-directed T-cell activation and antitumor activity by CD3/CD28 co-engagement. Immunotherapy 2024; 16: 143- 159.

[13] Cheng M , Santich BH , Xu H et al. Successful engineering of a highly potent single-chain variable-fragment (scFv) bispecific antibody to target disialoganglioside (GD2) positive tumors. Oncoimmunology 2016; 5: e1168557.

[14] Cheung LH , Zhao Y , Alvarez-Cienfuegos A et al. Development of a human immuno-oncology therapeutic agent targeting HER2: targeted delivery of granzyme B. J Exp Clin Cancer Res 2019; 38: 332.

[15] Claus C , Ferrara C , Xu W et al. Tumor-targeted 4-1BB agonists for combination with T cell bispecific antibodies as offthe-shelf therapy. Sci Transl Med 2019; 11: eaav5989.

[16] Ding Z , Sun S , Wang X et al. Nanobody-based trispecific T cell engager (Nb-TriTE) enhances therapeutic efficacy by overcoming tumor-mediated immunosuppression. J Hematol Oncol 2023; 16: 115.

[17] Du J , Cao Y , Liu Y et al. Engineering bifunctional antibodies with constant region fusion architectures. J Am Chem Soc 2017; 139: 18607- 18615.

[18] Einsele H , Borghaei H , Orlowski RZ et al. The BiTE (bispecific T-cell engager) platform: Development and future potential of a targeted immuno-oncology therapy across tumor types. Cancer 2020; 126: 3192- 3201.

[19] Eslami M , Schneider P . Function, occurrence and inhibition of different forms of BAFF. Curr Opin Immunol 2021; 71: 75- 80.

[20] Falchi L , Vardhana SA , Salles GA . Bispecific antibodies for the treatment of B-cell lymphoma: promises, unknowns, and opportunities. Blood 2023; 141: 467- 480.

[21] Friberg G , Reese D . Blinatumomab (Blincyto): lessons learned from the bispecific t-cell engager (BiTE) in acute lymphocytic leukemia (ALL). Ann Oncol 2017; 28: 2009- 2012.

[22] Gauthier L , Morel A , Anceriz N et al. Multifunctional natural killer cell engagers targeting NKp46 trigger protective tumor immunity. Cell 2019; 177: 1701- 1713.e16.

[23] Goebeler M-E , Stuhler G , Bargou R . Bispecific and multispecific antibodies in oncology: opportunities and challenges. Nat Rev Clin Oncol 2024; 21: 539- 560.

[24] Holstein SA , Grant SJ , Wildes TM . Chimeric antigen receptor T-cell and bispecific antibody therapy in multiple myeloma: moving into the future. J Clin Oncol 2023; 41: 4416- 4429.

[25] Jacobs SA , Gibbs AC , Conk M et al. Fusion to a highly stable consensus albumin binding domain allows for tunable pharmacokinetics. Protein Eng Des Sel 2015; 28: 385- 393.

[26] Klein C , Brinkmann U , Reichert JM et al. The present and future of bispecific antibodies for cancer therapy. Nat Rev Drug Discov 2024; 23: 301- 319.

[27] Klinger M , Brandl C , Zugmaier G et al. Immunopharmacologic response of patients with B-lineage acute lymphoblastic leukemia to continuous infusion of T cell-engaging CD19/CD3-bispecific BiTE antibody blinatumomab. Blood 2012; 119: 6226- 6233.

[28] Kontermann RE . Strategies to extend plasma half-lives of recombinant antibodies. BioDrugs 2009; 23: 93- 109.

[29] Labrijn AF , Janmaat ML , Reichert JM et al. Bispecific antibodies: a mechanistic review of the pipeline. Nat Rev Drug Discov 2019; 18: 585- 608.

[30] Li J , Stagg NJ , Johnston J et al. Membrane-proximal epitope facilitates efficient T cell synapse formation by antiFcRH5/CD3 and is a requirement for myeloma cell killing. Cancer Cell 2017; 31: 383- 395.

[31] Li H , Er Saw P , Song E . Challenges and strategies for nextgeneration bispecific antibody-based antitumor therapeutics. Cell Mol Immunol 2020; 17: 451- 461.

[32] Li G , Zhang Q , Liu Z et al. TriBAFF-CAR-T cells eliminate B-cell malignancies with BAFFR-expression and CD19 antigen loss. Cancer Cell Int 2021; 21: 223.

[33] Li S , Shi L , Zhao L et al. Split-design approach enhances the therapeutic efficacy of ligand-based CAR-T cells against multiple B-cell malignancies. Nat Commun 2024; 15: 9751.

[34] Liu D , Qi X , Wei X et al. A Novel Her2/VEGFR2/CD3 trispecific antibody with an optimal structural design showed improved T-cell-redirecting antitumor efficacy. Theranostics 2022; 12: 7788- 7803.

[35] Lou H , Cao X . Antibody variable region engineering for improving cancer immunotherapy. Cancer Commun(Lond) 2022; 42: 804- 827.

[36] Lu J , Jiang G . The journey of CAR-T therapy in hematological malignancies. Mol Cancer 2022; 21: 194.

[37] Lyu M-A , Cheung LH , Hittelman WN et al. The rGel/BLyS fusion toxin specifically targets malignant B cells expressing the BLyS receptors BAFF-R, TACI, and BCMA. Mol Cancer Ther 2007; 6: 460- 470.

[38] Nilforoushzadeh MA , Heidari N , Heidari A et al. The role of BAFF and BAFF-R inhibitors in the treatment of immune thrombocytopenia; a focused review. Int Immunopharmacol 2024; 131: 111827.

[39] Parameswaran R , Yu M , Lyu MA et al. Treatment of acute lymphoblastic leukemia with an rGel/BLyS fusion toxin. Leukemia 2012; 26: 1786- 1796.

[40] Ramírez-Chacón A , Betriu-Méndez S , Bartoló-Ibars A et al. Ligand-based CAR-T cell: Different strategies to drive T cells in future new treatments. Front Immunol 2022; 13: 932559.

[41] Regula JT , Imhof-Jung S , Mølhøj M et al. Variable heavy-variable light domain and Fab-arm CrossMabs with charged residue exchanges to enforce correct light chain assembly. Protein Eng Des Sel 2018; 31: 289- 299.

[42] Santich BH , Park JA , Tran H et al. Interdomain spacing and spatial configuration drive the potency of IgG-[L]-scFv T cell bispecific antibodies. Sci Transl Med 2020; 12: eaax1315.

[43] Schaefer W , Regula JT , Bähner M et al. Immunoglobulin domain crossover as a generic approach for the production of bispecific IgG antibodies. Proc Natl Acad Sci U S A 2011; 108: 11187- 11192.

[44] Schmidts A , Ormhøj M , Choi BD et al. Rational design of a trimeric APRIL-based CAR-binding domain enables efficient targeting of multiple myeloma. Blood Adv 2019; 3: 3248- 3260.

[45] Seckinger A , Delgado JA , Moser S et al. Target expression, generation, preclinical activity, and pharmacokinetics of the BCMA-T cell bispecific antibody EM801 for multiple myeloma treatment. Cancer Cell 2017; 31: 396- 410.

[46] Seung E , Xing Z , Wu L et al. A trispecific antibody targeting HER2 and T cells inhibits breast cancer growth via CD4 cells. Nature 2022; 603: 328- 334.

[47] Srivastava S , Riddell SR . Engineering CAR-T cells: design concepts. Trends Immunol 2015; 36: 494- 502.

[48] Subklewe M . BiTEs better than CAR T cells. Blood Adv 2021; 5: 607- 612.

[49] Surowka M , Schaefer W , Klein C . Ten years in the making: application of CrossMab technology for the development of therapeutic bispecific antibodies and antibody fusion proteins. MAbs 2021; 13: 1967714.

[50] Tagami N , Yuda J , Goto Y . Current status of BAFF targeting immunotherapy in B-cell neoplasm. Int J Clin Oncol 2024; 29: 1676- 1683.

[51] Tan H , Su W , Zhang W et al. Albumin-binding domain extends half-life of glucagon-like peptide-1. Eur J Pharmacol 2021; 890: 173650.

[52] Tapia-Galisteo A , Álvarez-Vallina L , Sanz L . Bi- and trispecific immune cell engagers for immunotherapy of hematological malignancies. J Hematol Oncol 2023; 16: 83.

[53] Trabolsi A , Arumov A , Schatz JH . Bispecific antibodies and CAR-T cells: dueling immunotherapies for large B-cell lymphomas. Blood Cancer J 2024; 14: 27.

[54] Ullah MA , Mackay F . The BAFF-APRIL system in cancer. Cancers (Basel) 2023; 15: 1791.

[55] van de Donk NWCJ , Zweegman S . T-cell-engaging bispecific antibodies in cancer. Lancet 2023; 402: 142- 158.

[56] Velasquez MP , Bonifant CL , Gottschalk S . Redirecting T cells to hematological malignancies with bispecific antibodies. Blood 2018; 131: 30- 38.

[57] Wang R , Natarajan K , Margulies DH . Structural basis of the CD8 alpha beta/MHC class I interaction: focused recognition orients CD8 beta to a T cell proximal position. J Immunol 2009; 183: 2554- 2564.

[58] Wong DP , Roy NK , Zhang K et al. A BAFF ligand-based CAR-T cell targeting three receptors and multiple B cell cancers. Nat Commun 2022; 13: 217.

[59] Wu L , Seung E , Xu L et al. Trispecific antibodies enhance the therapeutic efficacy of tumor-directed T cells through T cell receptor co-stimulation. Nat Cancer 2020; 1: 86- 98.

[60] Xiao Q , Zhang X , Tu L et al. Size-dependent activation of CAR-T cells. Sci Immunol 2022; 7: eabl3995.

[61] Xu Y , Lee J , Tran C et al. Production of bispecific antibodies in "knobs-into-holes" using a cell-free expression system. MAbs 2015; 7: 231- 242.

[62] Zhang Y , Fang C , Wang RE et al. A tumor-targeted immune checkpoint blocker. Proc Natl Acad Sci U S A 2019; 116: 15889- 15894.

[63] Zhang Q , Qian M , Wu Y et al. Design and biological evaluation of novel long-acting adalimumab Fab conjugated with the albumin binding domain. Eur J Pharmacol 2021; 904: 174152.

[64] Zhao L , Li S , Wei X et al. A novel CD19/CD22/CD3 trispecific antibody enhances therapeutic efficacy and overcomes immune escape against B-ALL. Blood 2022; 140: 1790- 1802.

[65] Zhao L , Li S , Wei X et al. A novel loop-structure-based bispecific CAR that targets CD19 and CD22 with enhanced therapeutic efficacy against B-cell malignances. Protein Cell 2024; 16: 227- 231.

[66] Zheng R , Zhu X , Xiao Y . Advances in CAR-T-cell therapy in T-cell malignancies. J Hematol Oncol 2024; 17: 49.

[67] Zuch de Zafra CL , Fajardo F , Zhong W et al. Targeting multiple myeloma with AMG 424, a novel anti-CD38/CD3 bispecific T-cell-recruiting antibody optimized for cytotoxicity and cytokine release. Clin Cancer Res 2019; 25: 3921- 3933.

RIGHTS & PERMISSIONS

The Author(s). Published by Oxford University Press on behalf of Higher Education Press.